A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Mark Herzberg is a Professor of Clinical Haematology involved in clinical trials for patients with blood cancers, particularly lymphoma, leukaemia, and myeloma, in Australia and New Zealand.
Hodgkin lymphoma is a common cancer with varied symptoms, and treatment typically involves chemotherapy and sometimes radiation therapy.
Approximately 800 Australian patients are diagnosed with advanced stage Hodgkin lymphoma each year, with staging determined through imaging and blood tests.
Advanced stage Hodgkin lymphoma is treated with outpatient combination chemotherapy using two major regimens (ABVD and escalated BEACOPP) worldwide, with a global clinical trial involving nine cooperative groups in nine countries and 1500 patients.
The ALLG contributed 115 patients across 16 sites in Australia and New Zealand to a groundbreaking clinical trial.
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen incorporating a new drug, Brentuximab Vedotin.
Patients experienced fewer side effects, such as anaemia, low platelet counts, peripheral neuropathy, and gonadal toxicity, while preserving fertility, with the modified BrECADD regimen in the treatment of advanced stage Hodgkin lymphoma.
Most patients with advanced stage Hodgkin lymphoma remained disease-free after three years of treatment, with a significant reduction in toxicity and shorter duration of treatment, allowing them to resume normal life and work sooner.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
-
Representing the profession that impacts individual lives and communities
Michelle Oliver is a highly experienced Occupational Therapist with nearly two decades of leadership and clinical expertise across the mental health, homelessness, and disability sectors. She holds a Master of Occupational Therapy from the University of South Australia and is a registered practitioner with AHPRA.
-
Autonomy in Emergency Nurse Practitioner role
Stefanie Edson is a dedicated Nurse Practitioner specialising in Emergency Care, with a strong commitment to improving patient outcomes. As the Tasmanian State Chapter Secretary for the Australian College of Nurse Practitioners (ACNP), Stefanie advocates for the growth and recognition of the Nurse Practitioner profession across Tasmania and beyond.
-
Allied Health Leader shares career insights
Mirella Vagnarelli is a distinguished healthcare leader with proven expertise across South Australia and the United Kingdom, where she has successfully led large, multidisciplinary teams. Holding a Master of Business Administration (Health) from Flinders University, she earned Fellowship status with the Australasian College of Health Service Management in 2022. In 2023, Mirella was honoured as a scholarship recipient for the prestigious ‘Women in Leadership’ Program at the Monash Centre for Health Research and Implementation.
